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ABSTRACT
The importance of renal biopsy in systemic lupus erythematosus (SLE) patients with nephritis
resides not only in the diagnosis, but mostly in its role in guiding and assessing therapy. The
potential benefits of treatment in lupus nephritis include a dramatic clinical improvement and a
direct impact on renal survival. However, these benefits can be achieved only if they are carefully
weighed against the complex, prolonged, and potentially toxic treatment regimens. This review on
lupus nephritis emphasizes on the histological appraisal of lupus nephritis, which may demonstrate
some variations among institutions, but should be clearly defined if one expects to have more
useful information for the routine management of patients, as well as in clinical trials.
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INTRODUCTION
Lupus nephritis and IgA nephropathy are by far the two
most common conditions encountered in renal biopsies
in our institution, and each accounts for over 30% of the
cases every year (1,2). The high incidence of IgA
nephropathy in biopsies reflects its being the most
prevalent glomerulonephritis worldwide, and such
nephropathy rarely requires a repeat biopsy (1,3). In
contrast, the prevalence of lupus nephritis in biopsies
reflects the relatively frequent repeat examination to
guide treatment and to assess therapeutic response.
Although lupus nephritis is a serious complication of
systemic lupus erythematosus (SLE), current therapies
may result in dramatic clinical response and in improved
renal outcome. However, such benefits can be gained
only when they are carefully weighed against the often
prolonged and potentially toxic therapy. While
controversies exist over whether biopsy is required for
initial treatment, the importance of histological
classification and indices in the patient's management is
no longer controversial (4).
PATHOGENESIS OF SLE AND
LUPUS NEPHRITIS
The pathogenesis of SLE remains obscure. Although
genetic and racial predispositions appear to be important,
the prevalence and mortality of SLE are strikingly similar
in various parts of the world, including China or Hong
Kong (2,4,5). The risk factor for lupus nephritis in women
is attributed to estrogens, while androgens confer a
certain protection. Infective agents and environmental
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factors have always been suspected, but remain unproven
(3).
The wide range of autoantibodies produced in SLE with
tissue deposition or formation of immune complexes,
and the handling defect or "saturation" of the monocyte-
phagocytic system, all contribute to renal injury. The
effector mechanisms mediated by complements,
inflammatory cells, or cytokines leading to renal injury
are similar in lupus and in other non-lupus nephritis (4).
CLINICAL MANIFESTATIONS IN
LUPUS NEPHRITIS
Renal manifestations in SLE are highly variable, and
often not well correlated with renal pathology. Only few
patients with SLE show urinary abnormalities early in
their course. Proteinuria and nephrotic syndrome are
dominant features, but microscopic hematuria is also
common. Hypertension is as common in SLE patients
with nephritis as in those without. Over half of SLE
patients demonstrate some impairment of renal function,
but only few present with acute renal failure (4). Tubular
dysfunction leads to increased light chains and beta 2-
microglobulin excretion, and renal tubular acidosis of
both hypokalemic and hyperkalemic types (4). The
clinical approach to lupus nephritis must consider the
patient as a whole, where extrarenal disease may be
dominant. The initial presentations are often non-renal,
even in patients who later develop severe nephritis.
ANTIPHOSPHOLIPID  ANTIBODIES
AND  THE  "LUPUS  ANTICOAGULANT"
The "lupus anticoagulant" activity is a misnomer, since
the antiphospholipid antibodies are directed against the
beta 2-globulin carrier protein rather than the
phospholipid itself. They increase the risk of thrombosis
in vivo for unknown reason, in contrast to anticoagulation
in vitro. These antibodies are detected in up to 50% of
patients with lupus nephritis, and have been associated
with renal and extrarenal thrombosis. However, true
lupus anticoagulant exists, due to antibodies to factors
VIII, IX, XI and XII, and their presence requires fresh-
frozen plasma coverage for renal biopsy.
DIAGNOSIS AND IMMUNOLOGIC
TESTS
Although the diagnosis of SLE is usually not difficult,
many patients are first suspected for other rheumatic
disorders. Routine screening of all proteinuric patients
for antinuclear antibodies (ANAs) is helpful. Nephritis
is seen in a few patients with mixed connective tissue
disease, but a seropositive anti-Ro and anti-La, and
negative anti-dsDNA antibodies confirm the diagnosis.
The immunologic tests require at least a positive ANA,
but preferably a positive dsDNA. The Farr assay detects
high avidity anti-dsDNA antibodies, and both the
enzyme-linked immunosorbent assay (ELISA) and the
Crithidia Lucile kinetoplast test detect low avidity
antibodies. Anti-Sm antibodies are highly specific, but
present only in 30% of patients. Low serum complement
is common in untreated lupus nephritis, and may reflect
active renal lesions. SLE may mimic Henoch-Schönlein
purpura with rash on the lower limbs, but assay for anti-
neutrophil cytoplasmic antibody (ANCA) can be useful
to the diagnosis in the latter condition (4). SLE differs
from microscopic polyarteritis by a positive anti-dsDNA
serum and a negative anti-myeloperoxidase assay (6).
RENAL PATHOLOGY
The spectrum of lupus nephritis can be very broad, and
encompasses all possible glomerular reactions to injury.
The WHO classification of lupus nephritis is based on
the light microscopy of six predominant glomerular
lesions. This classification has been correlated with renal
prognosis, and has permitted establishment of successful
therapeutic protocols. While essential to the management
of lupus, the WHO classification no longer carries
prognostic value following treatment (4). A more
dynamic assessment of lupus nephritis has been
developed at the National Institute of Health (NIH), with
the semiquantitative determination of disease activity and
Table 1.  Simplified WHO classification of lupus nephritis.
Class I Minor glomerular abnormality
Class II Pure mesangial lesions (mesangiopathic)
Class III Focal segmental lesions (necrosis, sclerosis, or both)
Class IV Diffuse glomerulonephritis
(with/without necrotizing or sclerosing lesions)
Class V Membranous nephropathy
Class IV Advanced sclerosing glomerulonephritis
Table 2.  Activity and chronicity indices in lupus nephritis (NIH).
Active lesions (maximum score of 24)
1. Endocapillary hypercellularity
2. Necrotizing lesions
3. Extracapillary proliferation (crescents)
4. Leukocytes infiltration
5. Hyaline changes (wire loops, thrombi)
6. Tubulointerstitial inflammatory cells infiltrate
Chronic lesions (maximum score of 12)
1. Glomerular obsolescence
2. Fibrous crescents
3. Tubular atrophy
4. Interstitial fibrosis
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chronicity, which has been correlated with short- and
long-term renal outcome, and thus plays an important
role in guiding and assessing therapy (4,7). The WHO
classification and NIH indices used at the Prince of Wales
Hospital are both simplified in table 1 and table 2,
respectively.
WHO CLASSIFICATION
This classification deals only with glomerular lesions,
with no reflection on tubular or extraglomerular vascular
disease. Although the 1995 modified version has
improved from the original 1982 WHO classification, it
would be unrealistic to believe that any case of lupus
nephritis fits exactly into one of the six categories. In
fact, many subdivisions in this classification have been
made, in an attempt to encompass the frequent
morphologic overlaping between the defined categories.
These subdivisions have caused some confusions, and
have been partly clarified in the 1995 modified
classification. We believe that such subdivisions should
be simplified to those which are clinically relevant, and
useful in predicting renal outcome prior to therapy. In
the Prince of Wales Hospital, the histological assessment,
which include the classification and appraisal of activity
and chronicity indices, is based on a minimum of 10
glomeruli, 5 mm cortex, and three arterioles.
Class I and Class II
Patients with class I or II nephritis may present with
modest or even no clinical disease. All patients with class
I and most with class II will have a benign course, even
without treatment. On histology, class I shows normal
glomeruli or glomeruli with minor abnormality, with no
distinction made on the presence or absence of immune
complexes, which are usually modest in amount. Class
II mesangiopathic disease (Fig. 1) refers to mesangial
expansion due to either hypercellularity (three or more
cell per mesangial area), or sclerosis, or both, associated
with mesangial immune complexes.
Class III
Class III is characterized by segmental lesions, which
may include necrosis, sclerosis, endocapillary
proliferation, crescent or any combination of these lesions
(Fig. 2). Based on clinicopathologic observations, we
have adopted the subdivision of class III nephritis
advocated by some into a low-grade and a high-grade,
corresponding to segmental lesions present in less than
50% and in 50% or more of the glomeruli, respectively
(8,9). However, the clinical relevance of such
subdivisions remains to be established by prospective
studies, which may require the use of activity indices in
the subdivisions (8-10). Such a high-grade class III
requires similar treatment as in class IV nephritis.
Figure 1.  Glomerulus in class II mesangiopathic alteration exhibits
intact tufts architecture, and at least mild mesangial matrix
expansion and/or three mesangial cells per area. Periodic acid-
silver methenamine, x 340.
Figure 2.  Class III lupus nephritis demonstrates a segmental
necrotizing lesion, featuring here capillary wall disruption, nuclear
fragmentation, and polymorphs infiltration. Periodic acid-silver
methenamine, x 320.
Figure 3.  Global endocapillary hypercellularity with extensive
obliteration of capillary lumen, and such lesion usually affects most
glomeruli in class IV nephritis. Periodic acid-silver methenamine,
x 340.
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Class IV
Class IV represents the most common renal lesions
biopsied, reflecting their overt clinical manifestations,
and is characterized by diffuse and global endocapillary
hypercellularity with or without cellular crescent (Fig.
3). While this global glomerular lesion may mask features
of other classes, this would not alter the immediate
treatment. Other features commonly seen include "wire-
loops", hematoxyphil bodies, necrotizing lesions, which
may be superimposed with sclerosis, disruption of
Bowman's capsule and glomerular distortion in the more
protracted case.
Class V
Lupus membranous nephropathy may be in pure form
with classical spikes and dome pattern on silver stain,
and characterized by predominant subepithelial immune
complexes, or be mixed with or masked by lesions from
other classes (Fig. 4). Renal vein thrombosis may
complicate such class V lesions.
The 1995 modification of the WHO classification had
reduced the number of subdivisions, and made it simpler
to use and reproduce among institutions. Our simplified
classification has gone one step further, and eliminated
the subdivisions, since secondary histological features
that make these subdivisions can be included in the
assessment of activity and chronicity indices. For
examples, class V nephritis associated with focal
segmental necrotizing lesions or with global
endocapillary proliferation, formerly classified as Vc or
Vd respectively, are now simplified as classes III and V,
or classes IV and V, respectively. The principle is to
identify, in a case of lesions, from various classes in a
first step, and subsequently report the classes that are
clinically relevant.  For example, a case with lesions of
classes II, III, IV and V is reported as class IV and V.
Keeping in mind that a biopsy represents the renal lesions
at one point in time, and may not reflect the dynamic
process of a nephritis, and that lesions overlap between
classes, the concept of progression or "transformation"
among WHO classes of lupus nephritis appears to be
over-simplified. However, interpreted as such, these
"transformations" are common, especially following
successful therapy (4,11). In fact, only histological
features useful to guide treatment are relevant, and the
activity and chronicity indices are much more
informative and important in the management of lupus
nephritis. Their role will get more important in clinical
trials.
Assessment of Activity and Chronic
Indices or Scores
The activity index is scored from all viable glomeruli,
excluding the obsolescent ones, and the chronicity index
is scored on all glomeruli present in sections. Each
activity and chronicity factor is graded on a scale of 0,1,
2,3 on a semiquantitative scale. Endocapillary
proliferation, leukocyte infiltration and hyaline changes
are graded on the severity of lesion in individual
glomeruli. Cellular crescents, necrotizing lesions,
glomerular sclerosis (segmental or global) and fibrous
crescents are graded as 0 for absence, 1 for less than
25%, 2 for 25% to 50%, and 3 for more than 50% of
glomeruli affected. Interstitial infiltrates, tubular atrophy
and interstitial fibrosis are graded as 0 for absence, 1 for
less than 25%, 2 for 25% to 50%, and 3 for more than
50% of cortical areas affected. As defined by the NIH
scoring, cellular crescents and necrosis are weighed by
a factor of x2.
Figure 4.  Lupus membranous nephropathy in pure form with mildly
thickened capillary wall and inconspicuous spikes. Such lesion is
better demonstrated in immunofluorescence or ultrastructural
studies. Periodic acid-silver methenamine, x 320.
Figure 5.  A capillary loop exhibiting both subepithelial and
subendothelial (
*
) dense immune deposits, and the extent of
subendothelial deposition has been correlated with prognosis.
Uranyl acetate and lead citrate, x 12600.
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Immunopathology and Ultrastructures
Polyclonal immunoglobulins and polytypic complement
complexes in basement membrane and mesangium
constitute the hallmark of a "full house" pattern, which
characterizes lupus nephritis. IgG is predominant among
immunoglobulins which are associated with early
complements C1q, C4 as well as C3. Other immune
reactants such as properdin, complement B, C5b-9, IgE,
etc are not routinely used. Electron microscopy shows
the often-widespread distribution of dense immune
complexes in all three glomerular sites: subendothelium,
subepithelium and mesangium, with the former being
the most prominent (Fig. 5). Prominent subepithelial
deposits are seen in class V nephritis. Tubuloreticular
structures are commonly seen, but not specific to lupus
nephritis. The fingerprint pattern in dense deposits is
distinctive, but only seen in a few cases.
OTHER MORPHOLOGICAL
FEATURES
Patients with active nephritis may also demonstrate
tubular basement membrane (TBM) immune complex
and anti-TBM antibodies, associated with interstitial
infiltration by T lymphocytes and monocytes. Tubular
infiltration or "tubulitis" is common in active disease,
but interstitial fibrosis expands in chronic disease.
Tubulointerstitial nephritis may be prominent, progress
independently of glomerular lesions, and become
determinant in the progression of lupus nephritis. Hyaline
changes and fibrinoid lesions of arterioles may be seen,
but rarely intrarenal arteriolar thrombi. These lesions are
all associated with a poor prognosis. A few patients show
thrombotic microangiopathy and depressed plasminogen
activators (3,4).
Amyloidosis is rare in lupus, because acute-phase
proteins like amyloid A and C-reactive protein do not
rise in the plasma during clinical flares. Non-lupus
glomerulopathies, including dense-deposit disease,
pauci-immune necrotizing glomerulitis, hepatitis B virus,
Escherichia coli, human immunodeficiency virus, and
IgA nephropathy, have been reported (3,12-14).
CLINICOPATHOLOGIC
CORRELATIONS
SLE patients without clinical nephritis may show
significant glomerular disease in their biopsy, and they
may continue to show no clinical nephritis for several
years. SLE patients with clinical nephritis must have gone
through a period of occult disease, but the proportion of
patients with such a subclinical course is unknown. While
severe glomerular lesions tend to show severe clinical
manifestations, renal histology cannot be predicted with
certainty from the clinical features. WHO biopsy classes
are powerful determinants of outcome in untreated
patients, but not after treatment. Interstitial changes at
the time of biopsy correlate with glomerular filtration
rate (GFR) and the renal outcome. The anti-dsDNA
antibody levels are similar in all histologic classes.
TREATMENT OF LUPUS NEPHRITIS
In patients with no or minor urine abnormality with class
I or II nephritis, treatment is unnecessary. Whether
corticosteroids at this point might prevent subsequent
severe disease has never been tested. The group with
focal proliferative nephritis (class III) or severe diffuse
proliferative nephritis (class IV) would benefit most from
immunosuppression. There is no clear evidence of
improved outcome of membranous nephropathy (class
V) after treatment, but some of these patients progress
slowly to renal failure. The treatment of lupus nephritis
has two facets: one is the induction treatment of severe
acute life-threatening disease, with multisystem
involvement, and the other is the maintenance treatment
of chronic more indolent disease, where protection from
the side effects of treatment is increasingly important.
The evidence for treating all but the mildest types of
lupus nephritis with corticosteroids is very strong (4,9,
15). Corticosteroids may be complicated by peptic ulcers,
diabetes, Cushing appearance, osteoporosis, and gonadal
failure. Cyclophosphamide may also result in gonadal
failure. Azathioprine can be complicated by cholestasis,
pancreatitis and marrow failure. Life-threatening
infection may include disseminated herpes zoster and
cryptococcal meningitis.
Results of Treatment in Lupus Nephritis
The clinical course of lupus can no longer be considered
separately from the results of treatment, and the overall
mortality and renal survival has markedly improved
compared to 30 years ago (4). This has led to almost all
patients with lupus nephritis receiving treatment,
including those with mild nephritis. The 5-year actuarial
survival improved from 17% to 82% in patients with
class IV nephritis in 35 years, and from 44% to 82% for
all lupus nephritis (4). There is a gratifying response to
early treatment, followed by quiescent disease under
maintenance therapy. Some patients relapse during
quiescent state, and the frequency and intensity of flares
have partly been correlated with the intensity and
duration of immunosuppression. To date, less than 15%
of patients with lupus nephritis progress to end-stage
renal failure, and the main causes of death in these
patients include sepsis, cerebral lupus, and premature
cardiovascular disease. The proportion of end-stage renal
patients with "burnt-out" lupus has been exaggerated, as
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most patients on dialysis still require immunosuppression
(16). Results of transplantation are comparable to other
groups of patients, and recurrent disease in allograft is
rare. Morphologically, all active glomerular lesions are
potentially reversible with complete reversal of the
activity (11). The WHO classification after treatment is
no longer relevant to prognosis (4).
Factors Influencing Renal Outcome
Clinical factors predicting the outcome in lupus nephritis
include serum creatinine, hypertension, and perhaps
proteinuria. While controversy exists for age at onset,
smoking, black race, and hypercholesterolemia, indices
of clinical activity, number of clinical criteria at onset,
and the frequency of relapses also predict outcome. The
strongest laboratory predictor of outcome is anemia, but
low platelet count, low serum complements, and levels
of circulating anti-dsDNA antibodies also correlated with
a poor prognosis (4).
Histologically, there is little difference in outcome among
different WHO classes in treated patients. However,
cellular crescents, extensive subendothelial immune
deposits (Fig. 5), and tubulointerstitial disease point to a
poorer prognosis. Vascular lesions within the biopsy and
intraglomerular capillary thrombi have been associated
with unfavorable outcomes. Calculation of activity and
chronicity indices allows identification of high and low
risk groups for a poor outcome, and also permits
therapeutic decisions of when to use aggressive treatment
(4,9,15).
CONCLUSION  AND  PERSPECTIVES
The importance of histologic classification and indices
of activity and chronicity of lupus nephritis on the
management and prognosis of SLE patients is well
established and cannot be overemphasized. However, the
full impact of renal biopsy in the treatment of lupus
nephritis remains to be defined. The evidence supporting
an early biopsy and treatment of all but the mildest types
of lupus nephritis is very strong, especially if adverse
renal outcome is to be avoided by preventing
accumulative effect of irreversible renal damage. From
a prognostic viewpoint, the morphologic data enhances
clinical and serological predictors in the short-term and
long-term assessment of the renal outcome. ‘Watchful
observation of a mildly abnormal urinary sediment may
be a recipe for long-term grief. The risk of renal biopsy
pales in comparison with the long-term consequences
of watchful waiting’ (9).
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